[go: up one dir, main page]

PE20091486A1 - Derivado de pirrolopirimidina como inhibidor de la enzima pi3k - Google Patents

Derivado de pirrolopirimidina como inhibidor de la enzima pi3k

Info

Publication number
PE20091486A1
PE20091486A1 PE2009000176A PE2009000176A PE20091486A1 PE 20091486 A1 PE20091486 A1 PE 20091486A1 PE 2009000176 A PE2009000176 A PE 2009000176A PE 2009000176 A PE2009000176 A PE 2009000176A PE 20091486 A1 PE20091486 A1 PE 20091486A1
Authority
PE
Peru
Prior art keywords
pyrimidin
pirrolo
pi3k
inhibitor
morfolin
Prior art date
Application number
PE2009000176A
Other languages
English (en)
Inventor
Hirosato Ebiike
Jun Ohwada
Kohei Koyama
Takeshi Murata
Woo Sang Hong
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of PE20091486A1 publication Critical patent/PE20091486A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)

Abstract

REFERIDA A UN DERIVADO DE PIRROLOPIRIMIDINA DE FORMULA (I), DONDE Q ES UN GRUPO LIGADOR -X-Y-; X ES UN ENLACE SIMPLE, CO, CONH, CSNH, ENTRE OTROS; Y ES UN ENLACE SIMPLE, ARILENO, HETEROARILENO, ENTRE OTROS; R1 ES ALQUILENO C0-C6-(A)m-ALQUILO C1-C6 O ALQUILO C0-C6-(A)m-ALQUILENO C0-C6-(HETEROCICLO); A ES CO, CS, CONH, CSNH, ENTRE OTROS; m ES 0 O 1. SON COMPUESTOS PREFERIDOS: 5-{7-[2-(4-ETIL-PIPERAZIN-1-IL)-PIRIDIN-4-IL]-2-MORFOLIN-4-IL-7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL}-PIRIMIDIN-2-ILAMINA, {3-[4-(2-AMINO-PIRIMIDIN-5-IL)-2-MORFOLIN-4-IL-PIRROLO[2,3-d]PIRIMIDIN-7-IL]-4-METIL-FENIL}-MORFOLIN-4-IL-METANONA, 5-(7-METANOSULFONIL-2-MORFOLIN-4-IL-7H-PIRROLO[2,3-d]PIRIMIDIN-4-IL)-PIRIMIDIN-2-ILAMINA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA Y A UN METODO DE PREPARACION. DICHOS COMPUESTOS SON INHIBIDORES DE LA ENZIMA PI3K Y SON UTILES EN EL TRATAMIENTO DEL CANCER, ENFERMEDADES PROLIFERATIVAS, ENTRE OTRAS
PE2009000176A 2008-02-07 2009-02-05 Derivado de pirrolopirimidina como inhibidor de la enzima pi3k PE20091486A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008027423 2008-02-07

Publications (1)

Publication Number Publication Date
PE20091486A1 true PE20091486A1 (es) 2009-10-14

Family

ID=40952235

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000176A PE20091486A1 (es) 2008-02-07 2009-02-05 Derivado de pirrolopirimidina como inhibidor de la enzima pi3k

Country Status (15)

Country Link
US (1) US20100324284A1 (es)
EP (1) EP2239261A4 (es)
JP (1) JP5350277B2 (es)
KR (1) KR20100120680A (es)
CN (1) CN101932584A (es)
AR (1) AR070352A1 (es)
AU (1) AU2009211622A1 (es)
BR (1) BRPI0907931A2 (es)
CA (1) CA2711778A1 (es)
CL (1) CL2009000241A1 (es)
IL (1) IL207452A0 (es)
MX (1) MX2010008686A (es)
PE (1) PE20091486A1 (es)
TW (1) TW200938201A (es)
WO (1) WO2009099163A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101889015B (zh) 2007-10-05 2014-06-04 维拉斯通股份有限公司 嘧啶取代的嘌呤衍生物
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
JP5877064B2 (ja) * 2008-11-11 2016-03-02 エックスカバリー ホールディング カンパニー エルエルシー ＰＩ３Ｋ／ｍＴＯＲキナーゼ阻害剤
NZ595372A (en) 2009-03-27 2013-11-29 Vetdc Inc Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
RU2506264C2 (ru) 2009-04-03 2014-02-10 Вэрастэм, Инк. Пиримидин-замещенные пуриновые соединения в качестве ингибиторов киназы (или киназ)
DK3072890T3 (en) 2009-07-07 2019-02-11 Mei Pharma Inc Pyrimidinyl and 1,3,5-triazinylbenzimidazoles and their use in cancer therapy
ES2608967T3 (es) 2011-03-28 2017-04-17 Mei Pharma, Inc. (Aralquilamino sustituido en alfa y heteroarilalquilamino)pirimidinil y 1,3,5-triazinil benzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para usar en el tratamiento de enfermedades proliferativas
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
CN103450204B (zh) * 2012-05-31 2016-08-17 中国科学院上海药物研究所 吡咯[2，1-f][1，2，4]并三嗪类化合物，其制备方法及用途
EP2968537A1 (en) 2013-03-15 2016-01-20 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
SG11201602446VA (en) * 2013-10-16 2016-05-30 Shanghai Yingli Pharm Co Ltd Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof
EP4012049A3 (en) 2014-04-04 2022-08-24 Crown Bioscience, Inc. (Taicang) Methods for determining responsiveness to mek/erk inhibitors
JP6659850B2 (ja) * 2015-12-31 2020-03-04 シャンハイ ファーマシューティカルズ ホールディング カンパニー，リミティド キノリン系化合物の塩、その結晶形、調製方法、組成物及び用途
TW201817731A (zh) * 2016-09-29 2018-05-16 日商第一三共股份有限公司 ［２－（１－甲基－１ｈ－吡唑－４－基）－６－（ 啉－４－基）－９ｈ－嘌呤－８－基］［４－（ 啉－４－基）哌啶－１－基］甲酮及其製藥上容許鹽之結晶
CA3063976A1 (en) 2017-05-23 2018-11-29 Mei Pharma, Inc. Combination therapy
RU2020109775A (ru) 2017-08-14 2021-09-16 Мей Фарма, Инк. Комплексная терапия
IT201800004082A1 (it) * 2018-03-29 2019-09-29 Berlin Chemie Ag Composizioni farmaceutiche antitumorali per terapia combinata
CN113200969B (zh) * 2021-05-19 2022-11-25 中国药科大学 一种PI3Kα选择性抑制剂及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE139232T1 (de) 1989-10-11 1996-06-15 Teijin Ltd Bizyklische pyrimidinderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung
ATE197051T1 (de) * 1992-04-03 2000-11-15 Upjohn Co Pharmazeutisch wirksame bicyclisch heterocyclische amine
US5502187A (en) * 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
JP3649395B2 (ja) * 2000-04-27 2005-05-18 山之内製薬株式会社 縮合ヘテロアリール誘導体
GB0100622D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds V111
UY29177A1 (es) * 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
US20090163490A1 (en) * 2006-03-11 2009-06-25 Vernalis (R&D) Ltd. Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors
SI2050749T1 (en) * 2006-08-08 2018-04-30 Chugai Seiyaku Kabushiki Kaisha DERIVAT PYRIMIDINE AS A PI3K INHIBITOR AND ITS USE

Also Published As

Publication number Publication date
AR070352A1 (es) 2010-03-31
CN101932584A (zh) 2010-12-29
EP2239261A4 (en) 2011-06-08
JP5350277B2 (ja) 2013-11-27
KR20100120680A (ko) 2010-11-16
CA2711778A1 (en) 2009-08-13
CL2009000241A1 (es) 2010-09-03
MX2010008686A (es) 2010-08-30
AU2009211622A1 (en) 2009-08-13
TW200938201A (en) 2009-09-16
BRPI0907931A2 (pt) 2015-07-28
EP2239261A1 (en) 2010-10-13
US20100324284A1 (en) 2010-12-23
IL207452A0 (en) 2010-12-30
JPWO2009099163A1 (ja) 2011-05-26
WO2009099163A1 (ja) 2009-08-13

Similar Documents

Publication Publication Date Title
PE20091486A1 (es) Derivado de pirrolopirimidina como inhibidor de la enzima pi3k
PE20110419A1 (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk
PE20070833A1 (es) Compuestos de pirimidinil benzotiofeno
DK2029547T3 (da) FXR-agonister
PE20140378A1 (es) Compuestos y composiciones como inhibidores de la trk
PE20121335A1 (es) Compuestos derivados de amida como inhibidores de raf cinasas
PE20100156A1 (es) Tratamiento de nafld
PE20080951A1 (es) DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
EA201291356A1 (ru) Пиперидиноновые производные как ингибиторы mdm2 для лечения рака
PE20091720A1 (es) Compuestos de benzopirano y benzoxepina como inhibidores de pi3k
PE20081353A1 (es) Compuestos del inhibidor de fosfoinositida 3-cinasa
PE20110796A1 (es) (s)-1-({4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il}-amida) de 2-amida del acido pirrolidin-1,2-dicarboxilico como inhibidor de la cinasa de fosfatidilinositol (pi3k)
EA201101618A1 (ru) Арилпиридины в качестве ингибиторов альдостеронсинтазы
PE20070427A1 (es) Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
PE20090649A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
PE20170247A1 (es) Derivados de pirrolidina-2,5-diona, composiciones farmaceuticas y metodos para usar como inhibidores ido1
PE20080527A1 (es) Derivado de pirimidina como inhibidor de la fosfatidilinositol 3-quinasa (pi3k)
PE20080948A1 (es) Derivados de imidazol como moduladores de la senda de hedgehog
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
PE20121506A1 (es) Compuestos triazolopiridinas como inhibidores de c-met
CO6440551A2 (es) Compuestos pirazolo[1,5-a]pirimidina sustituida como inhibidores de trk cinasa
PE20120184A1 (es) Derivados del pirrolo[2,3-b]piridina para la inhibicion de las proteinas quinasas raf
PE20080074A1 (es) Derivados de amida como agentes inhibidores de la quinasa c-fms
PE20060215A1 (es) 4-fenilamino-quinazolin-6-il-amidas

Legal Events

Date Code Title Description
FC Refusal